Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Our Impact, Partner Highlight All the Right Ingredients: The Founders of ArsenalBio Partner Highlight, Press Release NanoString and PICI Partner to Optimize Cell Therapies Announcement, Research Update Five Key Takeaways from ASCO 2021 Cancer Research Heroes, Patient Story When Cancer Becomes A Calling: Lacey Kitch Research Project Pancreatic Cancer Program Clinical Trial The REVOLUTION Trial Announcement, Our Impact, Research Update ASCO 2021: PICI Makes Progress in Toughest Tumor Types